Opus Genetics vs uniQure
IRD and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRD and QURE compare
uniQure is the larger company, worth 4.5 times as much as Opus Genetics ($1.5B against $336M).
uniQure grew revenue faster over the last twelve months (30.2% versus −36.1% for Opus Genetics).
Opus Genetics keeps more of each dollar of sales as profit, with a net margin of −1092% compared with −1351% at uniQure.
Opus Genetics scores higher on the StockData Score (5 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRD | QURE |
|---|---|---|
| Size and price | ||
| Market cap | $336M | $1.5B |
| Share price | $4.04 | $21.88 |
| Change, 1 year | 118% | −27.9% |
| Change, 5 years | −7.1% | −24.1% |
| Beta (5Y) | 0.10 | 3.07 |
| Employees | 27 | 221 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 4 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 34.1× (better) | 81.3× |
| P/B | – | 4.7× |
| FCF yield | – | −10.6% |
| Fair value | – | $6.38 |
| Margin of safety | – | −243% |
| Growth | ||
| Revenue growth (TTM) | −36.1% | 30.2% (better) |
| Revenue growth, 5Y average | – | −15.6% |
| Profitability | ||
| Gross margin | – | 92.5% |
| Operating margin | −513% (better) | −1072% |
| Net margin | −1092% (better) | −1351% |
| FCF margin | – | −865% |
| Return on equity | −4797% | −158% (better) |
| Financial health | ||
| Debt / equity | – | 0.15 |
| Interest coverage | −186.1× | −3.4× (better) |
| Current ratio | 12.19 (better) | 10.01 |
| Altman Z-score | −2.64 | −0.44 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −2.3% | – |
| Shareholder yield | −2.3% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 72.8% | 96.0% |
| Held by insiders | 37.6% | 2.1% |
| Insider net buying, 12 months | −$19.4M (better) | −$20.2M |
| Short interest, % of float | 20.9% | 12.5% |
Go deeper
- IRD stock overview
- IRD income statement
- IRD valuation and score
- QURE stock overview
- QURE income statement
- QURE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.